This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lipsitch, M.
Right arrow Articles by Levin, B. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lipsitch, M.
Right arrow Articles by Levin, B. R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, 02 1997, 363-373, Vol 41, No. 2
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

The population dynamics of antimicrobial chemotherapy

M Lipsitch and BR Levin
Department of Biology, Emory University, Atlanta, Georgia 30322, USA.

We present and analyze a series of mathematical models for the emergence of resistance during antibiotic treatment of an infected host. The models consider the population dynamics of antibiotic- sensitive and -resistant bacteria during the course of treatment and addresses the following problems: (i) the probability of obtaining a resistant mutant during the course of treatment as a function of antibiotic exposure; (ii) the conditions under which high, infrequent doses of an antibiotic are predicted to succeed in preventing the emergence of resistance; (iii) the conditions for the success of multiple drug treatment in suppressing the emergence of resistance and the relationship between antibiotic synergism and suppression of resistance; and (iv) the conditions under which nonadherence to the prescribed treatment regimen is predicted to result in treatment failure due to resistance. We analyze the predictions of the model for interpreting and extrapolating existing experimental studies of treatment efficacy and for optimizing treatment protocols to prevent the emergence of resistance.


This article has been cited by other articles:

  • Kesteman, A.-S., Ferran, A. A., Perrin-Guyomard, A., Laurentie, M., Sanders, P., Toutain, P.-L., Bousquet-Melou, A. (2009). Influence of Inoculum Size and Marbofloxacin Plasma Exposure on the Amplification of Resistant Subpopulations of Klebsiella pneumoniae in a Rat Lung Infection Model. Antimicrob. Agents Chemother. 53: 4740-4748 [Abstract] [Full Text]  
  • Udekwu, K. I., Parrish, N., Ankomah, P., Baquero, F., Levin, B. R. (2009). Functional relationship between bacterial cell density and the efficacy of antibiotics. J Antimicrob Chemother 63: 745-757 [Abstract] [Full Text]  
  • Hegreness, M., Shoresh, N., Damian, D., Hartl, D., Kishony, R. (2008). Accelerated evolution of resistance in multidrug environments. Proc. Natl. Acad. Sci. USA 105: 13977-13981 [Abstract] [Full Text]  
  • Zhao, X., Drlica, K. (2008). A unified anti-mutant dosing strategy. J Antimicrob Chemother 62: 434-436 [Abstract] [Full Text]  
  • Rozen, D. E., McGee, L., Levin, B. R., Klugman, K. P. (2007). Fitness Costs of Fluoroquinolone Resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51: 412-416 [Abstract] [Full Text]  
  • Chung, P., McNamara, P. J., Campion, J. J., Evans, M. E. (2006). Mechanism-Based Pharmacodynamic Models of Fluoroquinolone Resistance in Staphylococcus aureus.. Antimicrob. Agents Chemother. 50: 2957-2965 [Abstract] [Full Text]  
  • Andes, D., Forrest, A., Lepak, A., Nett, J., Marchillo, K., Lincoln, L. (2006). Impact of Antimicrobial Dosing Regimen on Evolution of Drug Resistance In Vivo: Fluconazole and Candida albicans.. Antimicrob. Agents Chemother. 50: 2374-2383 [Abstract] [Full Text]  
  • Andes, D., Lepak, A., Nett, J., Lincoln, L., Marchillo, K. (2006). In Vivo Fluconazole Pharmacodynamics and Resistance Development in a Previously Susceptible Candida albicans Population Examined by Microbiologic and Transcriptional Profiling.. Antimicrob. Agents Chemother. 50: 2384-2394 [Abstract] [Full Text]  
  • MacDougall, C., Polk, R. E. (2005). Antimicrobial Stewardship Programs in Health Care Systems. Clin. Microbiol. Rev. 18: 638-656 [Abstract] [Full Text]  
  • Filius, P. M. G., Gyssens, I. C., Kershof, I. M., Roovers, P. J. E., Ott, A., Vulto, A. G., Verbrugh, H. A., Endtz, H. P. (2005). Colonization and Resistance Dynamics of Gram-Negative Bacteria in Patients during and after Hospitalization. Antimicrob. Agents Chemother. 49: 2879-2886 [Abstract] [Full Text]  
  • Tam, V. H., Schilling, A. N., Nikolaou, M. (2005). Modelling time-kill studies to discern the pharmacodynamics of meropenem. J Antimicrob Chemother 55: 699-706 [Abstract] [Full Text]  
  • Pfister, P., Corti, N., Hobbie, S., Bruell, C., Zarivach, R., Yonath, A., Bottger, E. C. (2005). 23S rRNA base pair 2057-2611 determines ketolide susceptibility and fitness cost of the macrolide resistance mutation 2058A->G. Proc. Natl. Acad. Sci. USA 102: 5180-5185 [Abstract] [Full Text]  
  • Wiuff, C., Zappala, R. M., Regoes, R. R., Garner, K. N., Baquero, F., Levin, B. R. (2005). Phenotypic Tolerance: Antibiotic Enrichment of Noninherited Resistance in Bacterial Populations. Antimicrob. Agents Chemother. 49: 1483-1494 [Abstract] [Full Text]  
  • Campion, J. J., McNamara, P. J., Evans, M. E. (2005). Pharmacodynamic Modeling of Ciprofloxacin Resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 209-219 [Abstract] [Full Text]  
  • Oliver, A., Levin, B. R., Juan, C., Baquero, F., Blazquez, J. (2004). Hypermutation and the Preexistence of Antibiotic-Resistant Pseudomonas aeruginosa Mutants: Implications for Susceptibility Testing and Treatment of Chronic Infections. Antimicrob. Agents Chemother. 48: 4226-4233 [Abstract] [Full Text]  
  • Regoes, R. R., Wiuff, C., Zappala, R. M., Garner, K. N., Baquero, F., Levin, B. R. (2004). Pharmacodynamic Functions: a Multiparameter Approach to the Design of Antibiotic Treatment Regimens. Antimicrob. Agents Chemother. 48: 3670-3676 [Abstract] [Full Text]  
  • Gibello, A., Porrero, M. C., Blanco, M. M., Vela, A. I., Liebana, P., Moreno, M. A., Fernandez-Garayzabal, J. F., Dominguez, L. (2004). Analysis of the gyrA Gene of Clinical Yersinia ruckeri Isolates with Reduced Susceptibility to Quinolones. Appl. Environ. Microbiol. 70: 599-602 [Abstract] [Full Text]  
  • Rapp, R. P, Campion, J. J (2003). Challenges in Pharmacodynamic Studies of Antimicrobial Resistance. The Annals of Pharmacotherapy 37: 1329-1330 [Full Text]  
  • Martinez, J. L., Baquero, F. (2002). Interactions among Strategies Associated with Bacterial Infection: Pathogenicity, Epidemicity, and Antibiotic Resistance. Clin. Microbiol. Rev. 15: 647-679 [Abstract] [Full Text]  
  • Sander, P., Springer, B., Prammananan, T., Sturmfels, A., Kappler, M., Pletschette, M., Bottger, E. C. (2002). Fitness Cost of Chromosomal Drug Resistance-Conferring Mutations. Antimicrob. Agents Chemother. 46: 1204-1211 [Abstract] [Full Text]  
  • Turner, K M E, Garnett, G P (2002). The impact of the phase of an epidemic of sexually transmitted infection on the evolution of the organism. Sex. Transm. Infect. 78: i20-30 [Abstract] [Full Text]  
  • Bjorkholm, B., Sjolund, M., Falk, P. G., Berg, O. G., Engstrand, L., Andersson, D. I. (2001). Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori. Proc. Natl. Acad. Sci. USA 10.1073/pnas.241517298v1 [Abstract] [Full Text]  
  • Upcroft, P., Upcroft, J. A. (2001). Drug Targets and Mechanisms of Resistance in the Anaerobic Protozoa. Clin. Microbiol. Rev. 14: 150-164 [Abstract] [Full Text]  
  • Simpson, J. A., Watkins, E. R., Price, R. N., Aarons, L., Kyle, D. E., White, N. J. (2000). Mefloquine Pharmacokinetic-Pharmacodynamic Models: Implications for Dosing and Resistance. Antimicrob. Agents Chemother. 44: 3414-3424 [Abstract] [Full Text]  
  • Ribeiro, R. M., Bonhoeffer, S. (2000). Production of resistant HIV mutants during antiretroviral therapy. Proc. Natl. Acad. Sci. USA 97: 7681-7686 [Abstract] [Full Text]  
  • Amsden, G. W. (1999). Pneumococcal macrolide resistance—myth or reality?. J Antimicrob Chemother 44: 1-6 [Full Text]  
  • Gould, I. M. (1999). A review of the role of antibiotic policies in the control of antibiotic resistance. J Antimicrob Chemother 43: 459-465 [Abstract] [Full Text]  
  • Levin, B. R., Lipsitch, M., Bonhoeffer, S. (1999). Population Biology, Evolution, and Infectious Disease: Convergence and Synthesis. Science 283: 806-809 [Abstract] [Full Text]  
  • Bonhoeffer, S., Lipsitch, M., Levin, B. R. (1997). Evaluating treatment protocols to prevent antibiotic resistance. Proc. Natl. Acad. Sci. USA 94: 12106-12111 [Abstract] [Full Text]  
  • Bjorkholm, B., Sjolund, M., Falk, P. G., Berg, O. G., Engstrand, L., Andersson, D. I. (2001). Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori. Proc. Natl. Acad. Sci. USA 98: 14607-14612 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»